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Abstract
Temporal Localization of Insulin-Like Growth Factor 1 (Igf1) Positive Cells in
Developing Hypothyroid Brain
Name: Shelby Anne Kline
Degree: Master of Science in Biology
Institution: Minnesota State University, Mankato
Mankato, Minnesota, 2015.
Hypothyroidism has been known to result in numerous neuroanatomical defects in
the developing brain. To investigate further into the mechanism in which these defects
are obtained, local brain insulin-like growth factor 1 (Igf1) was investigated in relation to
the hypothyroid brain. There are many similarities between hypothyroidism and the Igf1
deficient brain. Additionally, TH (thyroid hormone) is known to interact with Igf1.
Therefore, the purpose of this study was to investigate the effect of induced congenital
hypothyroidism on the temporal expression of Igf1-positive cells in the brain.
To investigate the relationship between TH and Igf1 in the brain, we inhibited TH
production in C57BL6J mice by the administration of 1% KClO4 and 0.05% MMI in
drinking water from 14 (embryonic day 14) to P21 (postnatal day 21). Control and
hypothyroid mice were sacrificed at select developmental time points (P7, P14, P21,
P42). Serum was collected to measure Igf1 and T4 (thyroxine) by ELISA. Brain tissues
were collected and cryosectioned to obtain the frontal motor cortex, hippocampus, and
cerebellum, in which in situ hybridization was performed. From the in situ hybridization,
Igf1-positive cells and relative Igf1 mRNA levels were analyzed.
Serum T4 and Igf1 data was consistent with previous literature that indicated low
TH decreases Igf1 in the serum. Additionally, serum TH and serum Igf1 are positively

	
  

correlated and both peak in unison. Furthermore, also consistent with previous findings,
low TH resulted in a decrease of Igf1 mRNA in the brain. A significant reduction of Igf1positive cells was evident in the frontal motor cortex of hypothyroid treated animals, but
no other region, demonstrating region specific expression of Igf1-positive cells.
Additionally, we showed that the previously reported reduction of Igf1 mRNA in the
hypothyroid brain was not due to a decrease in Igf1 mRNA synthesis in the cortex,
hippocampus, or cerebellum, but potentially rather a total loss of Igf1-positive cells, like
that of the cortex.
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Introduction	
  
Thyroid hormone (TH) is essential for the proper development of many tissues,
including the brain. Low TH levels in development results in hypomyelination,
disorganized neuronal migrations, altered neurogenesis, and permanent neurological
defects. Although the lack of adequate TH at birth can now be detected and treated
within days, residual, irreversible neurological effects remain (Zoeller and Rovet 2004).
There are numerous cell types that are the target of TH, including astrocytes,
parvalbumin-containing interneurons, Purkinje cells, and oligodendrocytes. When TH
levels are below a tissue’s needs, the effects on these various cell types have a
detrimental influence on brain development. However, it is unknown whether the effects
of TH are direct, or indirect through another factor, such as local insulin-like growth
factor-1 (Igf1).
Insulin-like growth factor-1 interacts with TH, and therefore, could act as an
indirect regulator of TH signaling within the brain (Elder, Karayal et al. 2000). There are
several similarities in neuroanatomical defects associated with hypothyroidism or Igf1
deficiency to support this claim. When occurring during development, both states show a
significant reduction in the numbers of mature oligodendrocytes, ultimately leading to a
decrease in myelination and density of axons (McMorris, Smith et al. 1986, Beck,
Powell-Braxton et al. 1995, Gao, Apperly et al. 1998). Additionally, there is a total
reduction of parvalbumin containing neurons (PCNs) in the hypothyroid and Igf1 null
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brain (Beck, Powell-Braxton et al. 1995, Gilbert, Sui et al. 2007). Interestingly, Igf1 in
serum is decreased in hypothyroid individuals (Miell, Taylor et al. 1993). However, it is
largely unknown how changes in locally brain-produced Igf1 decrease during
hypothyroidism. Considering the evidence described above and the lack of our current
knowledge regarding Igf1 levels in the developing hypothyroid brain, our working
hypothesis is that: Low TH during development disrupts the temporal production of
Igf1 positive cells within the developing frontal motor cortex, hippocampus, and
cerebellum. The corollary hypothesis is that TH-induced reductions in local brainderived Igf1 result in neuroanatomical defects seen in mice lacking Igf1, suggesting that
neuroanatomical defects associated with low TH in development are due, in part, to
altered Igf1 signaling in the developing brain.
Literature Review
A. Regulations of TH Action
A.1—Receptors
Thyroid hormone action alters gene expression within the brain. Thyroid
receptors (TR) are ligand-regulating receptors that bind to DNA in the absence or
presence of T3 (triiodothyronine). TR act as heterodimers with retinoid X receptors
(RXR). Together, these receptors, in conjunction with available TH, determine
expression of specific target genes that direct development (Bernal 2002, Bernal 2007).
Two receptors for thyroid hormone exist, alpha and beta, encoded by the Thra gene or the
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Thrb gene respectively. The Thra gene produces two TR proteins through differential
splicing: TRα1 and TRα2. TRα1 is a bonafide receptor that binds T3, whereas TRα2 is an
isoform that binds DNA, but is unable to bind T3. The Thrb gene also produces two TR
proteins: TRβ1 and TRβ2. Both TRβ isoforms bind T3.
The highest expressions of TRα1 and TRα2 were found in the hippocampus,
cerebellar cortex, and the olfactory bulb, with TRα1 accounting for 70-80% of all the
receptors located in the cerebellum. This observation suggests that most affects of TH in
the brain are mediated by this receptor subtype (Bradley, Young et al. 1989, Bernal
2007). The greatest expression of TRβ1 was observed in the anterior pituitary and in the
paraventricular hypothalamic nuclei (PVN), with lower levels in other brain regions. The
expression of TRβ2 was highly restrictive, with expression largely restricted to the
anterior pituitary (Bradley, Young et al. 1989). Within the cerebellum, TRβ receptors
were expressed in Purkinje cells (Quignodon, Grijota-Martinez et al. 2007). Because of
overlapping, yet distinct expression of TRα1 and TRβ, different functional roles for each
of the corresponding receptors may exist (Bradley, Young et al. 1989).
A.2—Deiodinase Enzymes
The local availability of TH to bind TRs and regulate gene expression within
given tissues is controlled, in part, by deiodinase enzymes. Two deiodinase enzymes are
present in the murine brain: type II (Dio2) and type III (Dio3). The type II deiodinase
enzyme converts prohormone T4 (thyroxine) to the biologically active hormone, T3

	
  

13	
  

(triiodothyronine) (Figure 1). Dio2 is expressed primarily in two glial cells – tanycytes
that line the 3rd ventricle, and astrocytes. Dio3 is expressed primarily in neurons and
converts T4 to an inactive metabolite, reverse T3 (rT3), or T3 to the inactive metabolite
T2 (Figure 1). Both of these enzymes are critical in the homeostasis of TH in the brain,
and their spatial separation suggests a paracrine-like mechanism for TH functions within
brain tissue (Freitas, Gereben et al. 2010).

Figure 1. The conversion of iodothyronines by DIO2 and DIO3. The resulting products are
dependent on the removal of one specific iodine from the appropriate specific location, which
is dependent on either DIO2 or DIO3 (Nakao, Ono et al. 2008).

A.3—Gene Transcription
Gene regulation mediated by TH and TRs can possibly help explain
developmental defects associated with hypothyroidism
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(Quignodon, Grijota-Martinez et al. 2007). Although only a few direct targets of the TR
have been identified in the brain, these genes functionally relate to developmental
processes such as myelination, migration and differentiation of neuronal cells, and
synaptogenesis (Bernal 2002, Bernal 2007). Binding of T3 to either TR represses or
activates gene transcription, depending on multiple factors, such as the number of
available co-factors and the cis-regulatory element that the TR are bound to (Yen 2001).
The hormone-receptor complex binds specific DNA sequences called TH response
elements (TREs), which directly regulate specific genes (Chatterjee, Lee et al. 1989). As
stated, relatively few genes are direct targets of TH/TR; a subset of which are
transcription factors that can modulate the expression of other genes. These latter genes
do not directly interact with the TH-receptor complex and therefore lack TREs. These
findings were significant in showing that TH can modulate the expression of numerous
genes by indirect action (Gilbert and Zoeller 2010).
B.—Regulation of Igf1 Action
Igf1 is a growth factor that is essential for normal brain development. It is a
polypeptide genetically related to insulin, which also shares a similar tertiary structure
and amino acid identity to insulin. Although Igf1 production from the liver is most well
known, Igf1 is also produced locally in many tissues, including the brain. When
synthesized in the brain, growth hormone (GH) plays no significant regulatory role in its
synthesis, unlike Igf1 found in the serum
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(Bondy and Cheng 2004, Aberg, Brywe et al. 2006). This growth factor’s mRNA is
found to be abundant in the brain, especially at times of early postnatal development
(Bondy and Chin 1991). Expression of Igf1 in the murine brain begins around embryonic
day 14 (E14), and declines after the peak expression at approximately two weeks
postnatal, with expression, although lower, continuous throughout life (Bondy 1991,
D'Ercole, Ye et al. 1996). Like TH, Igf1 is also essential for proper myelination,
projection neuron growth, synaptogenesis, and dendritic arborization. During normal
brain development, it also promotes neuronal survival, especially in areas that depend on
postnatal neurogenesis, such as the hippocampus (Bondy and Cheng 2004).
B.1—Igf1 Receptors
Igf1 not only shows similarities to insulin in its structure, but also its receptor is a
close homologue, both in structure and sequence (LeRoith 1996). The receptors for both
insulin and Igf1 are receptor tyrosine kinases (RTK). Ligand binding to the Igf1 receptor
(Igf1r) results in RTK autophosphorylation and association with insulin receptor substrate
(IRS) adapter proteins with subsequent IRS phosphorylation. Insulin receptor substrate
phosphorylation leads to a signaling cascade that ultimately leads to transcriptional
changes. Igf1 receptors are concentrated in the brain in regions of neuron rich structures,
suggesting that Igf1’s actions are essential in modulating neuronal functio (Hill, Lesniak
et al. 1986, Bohannon, Corp et al. 1988). The highest amounts of Igf1r were found in the
olfactory bulb, dentate gyrus, cerebellum, piriform cortex, and the choroid plexus. The
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lower levels of expression, as detected by in situ hybridization, were found in white
matter tracts (Marks, Porte et al. 1991). This expression mimics that of Igf1 mRNA
expression localization, where the highest expression was found in the cerebellum,
olfactory bulb, and hippocampal complex, with expression rarely detected in white matter
tracts (Bartlett, Li et al. 1991). This close proximity of Igf1 mRNA expression and its
associated receptor expression goes to further support the theory of autocrine and/or
paracrine signaling of Igf1.
C.—Potential Interaction between TH and Igf1 in Nervous System Development
Igf1 and TH are both essential for proper neurological development, and
insufficiency of either factor results in permanent neurocognitive deficits. Interestingly,
many of the detrimental effects associated with hypothyroidism are similar to those
associated with Igf1 deficiency. Described below are examples of these effects, focusing
on the role of each factor of neurological development.
C.1—Neurogenesis
TH plays an imperative role in the development of the central nervous system.
Within the hippocampus, TH has been shown to increase the rate of neuroblast
proliferation of the subgranular zone (Montero-Pedrazuela, Venero et al. 2006). In
addition, an important function of TH in the brain is to regulate timing of differentiation
and end neuronal proliferation at optimal times (Lauder 1977). Upon terminal
differentiation and exit from the cell cycle, neurons migrate to their appropriate regions
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of the brain in an orderly pattern (Porterfield 1994). Hypothyroidism prevents neurons
from making reciprocal contacts by preventing migration and maintaining distances from
predestined target cells during critical times of development. An example of TH’s role in
cortical lamination can be seen in hypothyroid rats that shown disorganization within
their cerebellar cortex (Lauder 1977, Nunez 1984). This disorganization results from a
retarded spatio-temporal program leading to altered connectivity (Nunez 1984). TH is
also important for stimulating the formation and maturation of axons and dendrites,
which is essential for synaptic survival (Nunez 1984, Heisenberg, Thoenen et al. 1992).
Furthermore, the survival of neurons, at least in vitro, is dependent on adequate
concentrations of active TH (Heisenberg, Thoenen et al. 1992).
Similar to the effects of TH in development, Igf1 expression is also necessary for
proper neurogenesis and neuronal migrations. Igf1 has been shown to stimulate the
proliferation of neuronal progenitor cells, induce oligodendrocyte differentiation, and
increase the survival of oligodendrocytes and neurons (D'Ercole, Ye et al. 2002). In Igf1-/mice, a 59% reduction in volume of the dentate gyrus granule cell body layer was
observed when compared to controls. This further supports the neurogenic roll that Igf1
plays in the generation of cells, such as dentate granule neurons (Mozell and McMorris
1991, Beck, Powell-Braxton et al. 1995). Igf1 also promotes proper neuronal migrations
in structures such as the olfactory bulb. Without Igf1 expression in mice, the layering of
the olfactory bulb was altered, resulting in misplaced cells in the mitral and external
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plexiform layer and fewer neurons in the glomerular layer (Hurtado-Chong, Yusta-Boyo
et al. 2009).
C.2— Oligodendrocytes, Myelination, & Brain Size
Proliferation and maturation of oligodendrocytes begins in early postnatal life and
continues throughout adulthood, unlike neurons (Rodier 1980). Myelination of central
nervous system axons is completed by oligodendrocytes. Myelin electrically insulates
and surrounds axons with multilamellar compacted membranes (Farsetti, Mitsuhashi et
al. 1991). TH is necessary for proper brain myelination. Myelination is highly regulated
and is dependent on timing and differentiation of oligodendrocytes. The myelin
associated glycoprotein gene (MAG) is a key gene in the myelination process and the
expression of MAG is delayed in developmentally hypothyroid animals (Rodriguez-Pena,
Ibarrola et al. 1993). Furthermore, hypothyroidism significantly decreases the total
amount of myelination, as well as total brain size and weight (Gravel, Sasseville et al.
1990). Previous findings have demonstrated that TH controls the accumulation of mature
oligodendrocytes, in which case, hypothyroidism ultimately decreases the density of
myelinated axons present in the corpus callosum (Berbel, Guadano-Ferraz et al. 1994,
Schoonover, Seibel et al. 2004).
Similar to TH, Igf1 is also essential for myelination and oligodendrocyte
development. Igf1 increases the survival and development of myelin creating
oligodendrocytes, at least in vitro (Mozell and McMorris 1991). Differentiation of

	
  

19	
  

oligodendrocytes involves processes such as increasing cell process branching and
augmentation of myelin protein expression, along with myelin sheath production. Igf1 is
thought to stimulate the differentiation process for oligodendrocyte progenitor cells
(OPCs) by activating the MAPK and Akt pathways, and enhancing a regulator of the cellcycle progression (Chesik, De Keyser et al. 2008). Consistent with this idea, a decrease in
oligodendrocyte numbers is observed in Igf1 knockout mice (Beck, Powell-Braxton et al.
1995), whereas an overexpression of Igf1 in mice led to an increase in the number of
oligodendrocyte markers (Chesik, De Keyser et al. 2008). Interestingly, developmental
hypothyroidism also reduces the number of myelinating oligodendrocytes (Schoonover,
Seibel et al. 2004, Sharlin, Tighe et al. 2008). Therefore, an altered temporal expression
of Igf1 in the presence of low TH may decrease the numbers of mature oligodendrocytes.
Similar to the effect of developmental hypothyroidism, Igf1 inactivation results in
a decrease in brain size compared to wildtype animals. Furthermore, in mice lacking Igf1,
immunohistochemical staining found a significant decrease in myelin staining and an
overall net loss in the number of present axons, with the majority of the remaining axons
presenting unmyelinated characteristics. This decrease in myelin was more than twice as
much as the general reduction in brain size. The total number of oligodendrocytes in the
knockout mice was also significantly reduced. The corpus callosum, analyzed by electron
microscopy, was one of the regions in which the density of myelination was measured,
and showed a decrease when compared to wildtype subjects
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(Beck, Powell-Braxton et al. 1995). Similar effects on myelination are also noted in
developmentally hypothyroid animals (Gravel, Sasseville et al. 1990).
Treatment of primary brain cells with Igf1 following two days of culture resulted
in an increase in myelination by 35-90% when compared to untreated samples. However,
when treatment began after 20 days, a significant increase was not seen when compared
to controls (Mozell and McMorris 1991). This alludes that there is a time sensitive period
during development in which Igf1 is crucial to the myelination of axons in the developing
brain. This timing mechanism is similar to TH action on myelination, where T3
stimulates myelination largely during the perinatal period (Schoonover, Seibel et al.
2004).
C.3—Parvalbumin-Containing Neurons (PCNs)
Parvalbumin (PV) is a calcium binding protein that can be found in inhibitory
interneurons (McDonald and Betette 2001). Developmental hypothyroidism resulted in a
profound loss in PV-immunoreactivity (IR). These persistent affects on PCNs were
associated with functional deficits within inhibitory synaptic transmissions in the dentate
gyrus. Furthermore, this loss of PV-IR was observed with low-dose Proplythiouracil
(PTU; a thyroid hormone synthesis inhibitor) exposure, suggesting PV interneurons are
highly sensitive to disruption in TH action. Moreover, when animals were returned to
normal euthyroid status in adulthood, although some recovery of PV-IR ensued, a
permanent loss of PV-IR remained. This observation suggests that some of the PCNs had

	
  

21	
  

lost the full capacity to express PV in the absence of TH. Although there was some
recovery of PV-IR, there still resulted a lasting reduction, indicating that there was also a
total lost of PCNs. The absence of PV in the dendrites and soma of PCNs likely
contributes to the physiological disruption of neuronal firing observed following
developmental hypothyroidism (Gilbert, Sui et al. 2007).
Parvalbumin-containing neurons are not only dependent on TH, but also on Igf1.
The numbers of striatal PCNs in Igf1 knockout mice were significantly reduced
compared to wildtype animals (Beck, Powell-Braxton et al. 1995). Similarly, as discussed
above, developmentally hypothyroid animals also showed a decrease in PV-IR (Gilbert,
Sui et al. 2007). Considering this, it is tempting to speculate that altered Igf1 expression
in hypothyroid animals is responsible for the dramatic changes in PV-IR observed.
D.—Igf1 Action in the Developing Brain and Potential Cross-Talk with TH
There are many similarities between the effects associated with low TH and the
effects associated with low Igf1 within the developing mammalian central nervous
system. We hypothesized that neurological defects found in hypothyroid animals are due,
in part, from a decrease in local brain Igf1 production.
Additionally, we suggest that low TH alters brain development by shifting the
temporal expression of local brain Igf1 to later in life. This delay in expression could
potentially result in decreased progenitor pools of cells, and therefore decreased mature
cells within brain tissue, such as can be seen with oligodendrocytes
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(Beck, Powell-Braxton et al. 1995). It could also explain the disorganized migrations that
have been observed, as timing is imperative to such mechanisms (Lauder 1977, Nunez
1984). The timing of expression of key factors in the brain, such as Igf1, is compulsory.
If the timing mechanism of Igf1 were to be disrupted, and shifted to later in development,
it could explain some of the irreversible defects found in hypothyroidism.
TH could cause the progenitor pools that produce Igf1 to develop, proliferate, and
mature, which could be why a decrease is seen in local Igf1 in the brain under
hypothyroid conditions. If there were a decrease in cells that are capable of producing
Igf1, then there would result in a total reduction of local Igf1 mRNA expression.
Alternatively, TH could also possibly act as a positive regulator of local Igf1 production
through the TH receptor. Therefore, low TH would result in a direct decrease in local
Igf1 expression, which could result in the observed defects associated with
hypothyroidism and Igf1 deficiency. Which of these mechanisms contributes to the
defects observed in animals with low TH or Igf1 remains to be determined, and is a goal
of the proposed study.
Materials and Methods
Mouse Strains
This study utilized C57BL/6J mice, a highly inbred strain, originally purchased
from Jackson Laboratories. All animal procedures were approved by the MSU-Mankato
IACUC.
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Treatments
Timed-pregnant mice were divided into two groups: euthyroid and hypothyroid.
The sample size for each group, at each timepoint to be investigated, was n=4-6. All
treatments were administered via drinking water. The euthyroid group maintained normal
drinking water throughout with the addition of 0.01% bovine serum albumin (BSA).
Hypothyroid animals drinking water contained 0.02% methimizole (MMI), 1% potassium
perchlorate and 0.01% BSA. Treatment of pregnant dams was initiated on embryonic day
14 (E14) and continued until weaning on postnatal day 21 (P21).

Sacrifice & Dissection
Sacrifice and tissue collection occurred at the following time-points: P7, P14,
P21, and P42. Animals under the age of P10 were rapidly decapitated using sharp scissors
(as per protocol). Animals after the age of P10 were sedated using CO2 and then
decapitated to obtain the brain tissue. Using sterile techniques and tools, the skin of the
head was removed, followed by the skull. The brain was then removed from the cranial
cavity and immediately frozen in liquid nitrogen vapor and stored at -80oC until further
use. If gender was unable to be determined at the time of sacrifice, a small tail clipping
was collected at time of sacrifice and stored at -20oC for analysis of the SRY gene
through polymerase chain reaction (PCR) and gel electrophoresis.
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Genotyping of Pup Sex
Tails were digested in 500 microliters of tail lysis buffer (50mM Tris-Cl (pH8.0),
20mM NaCl, 1mM EDTA, 0.2% SDS, 200ug/ml Proteinase K (10mM Tris-Cl (pH 8.0),
20mM CaCl2, 50% Glycerol, ddH2O). The tails were dissolved at 56oC with constant
shaking. Once dissolved, the samples were centrifuged for five minutes at 14000rpm to
remove debris. Four hundred and fifty microliters of supernatant were placed into a clean
tube labeled accordingly. Four hundred and fifty microliters of isopropyl alcohol were
then added to each tube and inverted 8-10 times to mix. The samples were then quickly
centrifuged to pellet DNA at the bottom. Decanting of each tube then occurred, followed
by the addition of 200μl of ddH2O. The tubes were then placed at 56oC with constant
shaking for 15 minutes to dissolve DNA.
For SRY specific PCR, each PCR reaction received 1μl DNA, 0.4μl of the
forward and reverse SRY primer (10μM stock, IDT), 0.26μl of the forward and reverse
primer of Interleukin3 (10μM stock, IL3), 8.68μl of ddH20, and 10μl of 2x PCR
master mix (GoGreen Matermix, Promega). Each sample was then briefly vortexed and
centrifuged. Samples were then placed in a thermal cycler programmed for the following
conditions: 95oC for 4.5 minutes, followed by 33 cycles of 95oC for 35 seconds, 50oC for
one minute, and 72oC for one minute, finishing with 72oC for five minutes. An agarose
gel was prepared by mixing 25mls of 1xTBE (Tris/borate/EDTA) and 0.25g of agarose,
and heated to dissolve. Once dissolved, one drop of ethidium bromide (0.625mg/ml) was
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added and swirled to mix before pouring into the mold to set up. Once the gel had set, a
ladder and each sample (post PCR) were added into their individual wells. Voltage of
80V was applied to the gel electrophoresis chamber and allowed to run for approximately
one hour before stopping and analyzing results with ultraviolet (UV) light.

Collection of Trunk Blood & Analysis of Igf1 & T4
Immediately following decapitation, trunk blood was collected and held on ice for
no less than 20 minutes and no more than one hour. Blood was then centrifuged at 0.8rcf
for 10 minutes. Plasma was drawn off using a micropipette and placed into a clean,
properly labeled plasma tube to be held at -20oC until further use.

Cryosectioning
Frozen brain tissues were removed from the -80oC freezer, equilibrated to cryostat
temperature (-18 to -21oC) for approximately 30 minutes, mounted appropriately in
optimal cutting temperature medium (O.C.T.; Tissue-tek), and then sectioned at 12
microns. Three brain regions were collected and analyzed: frontal motor cortex,
hippocampus, and cerebellum. The cortex and hippocampus were sectioned coronally and
the cerebellum was sectioned in a sagittal direction. Sections were thaw mounted on
Superfrost Plus/Colorfast Plus Microslides (75x25mm; Daigger). To confirm correct
anatomic location, a single slide was fixed in ethanol, stained using methylene blue and
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visualized under a microscope. Once appropriate location had been confirmed, collection
continued. Six sections per animal per slide were mounted, and ten slides per region of
age-matched euthyroid and hypothyroid animals were collected on a single slide. After
collection was completed, the slides were stored appropriately at -80oC until further use.

In situ Hybridization
To elucidate the temporal and spatial pattern of Igf1 mRNA expression, in situ
hybridization was performed as follows. The slides with brain sections were removed
from the -80oC storage and allowed to warm to RT (room temperature) for approximately
15 minutes before being placed in an RNAse-free coplin jar. The slides were fixed in 4%
paraformaldehyde (PFA)/1x diethyl Pyrocarbonate treated (DEPC-Tx) PBS for 10
minutes followed by washing two times with 1xDEPC-Tx PBS for two minutes each
time. The sides were then acetylated with 0.1M triethanolamine (TEA)/0.25% Acetic
Anhydride for 10 minutes. After acetylation, the slides were washed three times in
1xDEPC-Tx PBS, each time for two minutes. The probe dilutions were heated to 80oC
for five minutes before immediate placement on ice. Approximately 250µl of the
probe/hybridization buffer dilutions were added to the slides, followed by coverslips. The
slides were placed in the hybridization chamber and allowed to sit overnight with 50%
formamide/0.2X saline-sodium citrate (SSC) moistened paper towels placed in the
bottom of the hybridization chamber. However, at this time, the chamber was also placed
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in a temperature-controlled environment (55-58oC). The next day, the coverslips were
removed and the slides were washed in pre-warmed (70-78oC) 0.2xSSC for about one
hour at 70-78oC. During this wash, the solution was changed after 5, 15, 15, and 15
minutes respectively. The slides were then allowed to cool to RT and washed again with
RT 0.2xSSC for five minutes. Next, the slides were washed in maleic acid buffer (MB)
for five minutes, at RT. Following the removal of the MB wash, thirty milliliters of 2%
MBMB (Roche) blocking buffer was added to the coplin jars and allowed to equilibrate
for one hour at RT. Each slide was individually removed from the chamber and covered
with 500µl of anit-digoxigenin antibody (anti-DIG-AP) (diluted to 1:2000 2% MBMB)
and allowed to incubate overnight. On day three, the slides were washed two times in MB
for 30 minutes each. Then they were washed twice in color reaction buffer for 30 minutes
each to allow the pH to adjust. Five hundred microliters of color reaction mix (color
reaction buffer with the addition of 200µl nitro-blue tetrazolium and 5-bromo-4-chloro3’-indolyphosphate (NBT/BCIP) per 10ml of color reaction buffer) were pipetted onto
the slides in a hybridization chamber. The chamber also encased wetted (with molecular
grade water) paper towels, and it was protected from light over night (approximately 18
hours). On the last day, the slides were washed in 1xPBS for five minutes. Glass
coverslips (24x50) were mounted to the slides using Aqua/Poly mount. The slides were
allowed to dry for no less than 30 minutes before examining.
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Quantification of Igf1-Positive Cells
Using ImageJ, a RGB photomicrograph was converted to a gray scale image.
Then, a standard threshold was applied to all images such that the in situ signal was
selected with little background. Then, the integrated density (gray value x thresholded
pixel area) was quantified. Specific brain regions were quantified as follows: For the
cortex, a 550um x 550um (302.5um2) box was drawn in the first cortical layer, directly
adjacent to the midline. The threshold was set to 65-255 grey values and anything smaller
than 25um was not counted as a cell. For the analysis of the molecular layer of the
hippocampus, the entire hippocampal molecular layer region was outlined and brought to
a threshold of 65-255 grey values, with anything smaller than 25um being excluded from
the count (Figure 2). For the cerebellum, the paramedian lobule (PM) was analyzed. A
line was drawn directly over the Igf1-positively stained cells in the PM between 10002000um. Only the cells along that line were analyzed (representing purkinje layer).
Figure 2 demonstrates the analysis process of the hippocampus.
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Figure 2. Data analysis process of the hippocampus. (A) RGB colored photomicrograph (B) the same
photomicrograph converted to gray scale. (C) The hippocampal area to be analyzed was then outlined (D)
and cropped and zoomed in on. (E) The threshold was set to 65-255 gray values. (F) The outlined area was
then analyzed, with anything smaller than 25um not being included in the analysis, resulting with the total
Igf1-positive cell numbers and integrated density values.

To determine whether there was significant affect of treatment on Igf1-postive
mean cell numbers, a two-way ANOVA was used to analyze differences of treatment,
time, and an interaction between variables for ages P7-P21. A post-hoc Bonferroni’s ttest was used to identify significant differences between treatments. An affect of
treatment on Igf1-postive cell numbers at P42 was determined using an unpaired t-test.
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Quantification of Relative Igf1 mRNA Levels
To determine whether there was significant affect of treatment on relative cellular
Igf1 mRNA levels, the in situ signal was quantified as an integrated density. For all
regions analyzed, the integrated density was calculated from the same cropped,
thresholded images that were used for the cellular count analysis. For integrated density
data in the cerebellum, a 25um x 25um circle was drawn and then placed over identified
cells and the integrated density was measured of each cell. A two-way ANOVA was used
to analyze differences of treatment, time, and an interaction between variables for ages
P7-P21. If significance was determined, a Bonferroni’s post-hoc t-test was used to
identify significant differences between treatments. For animals aged P42, an unpaired ttest was used to determine significant differences between treatments.

Enzyme-Linked Immunosorbent Assay (ELISA)
To measure Igf1 and T4 serum levels, ELISA was performed on collected serum.
First, the desired number of coated wells were secured into the holder. A data sheet was
made with sample identification.
T4 ELISA.
Twenty-five microliters of standards, experimental samples, and controls were
dispensed into the appropriate wells. Next, 100µl of the working (1:10) Enzyme
Conjugate Reagent were dispensed into each well. Each well was thoroughly and
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completely mixed for 10 seconds. The samples were then incubated at RT for 60 minutes.
The incubation mixture was then removed by flicking the plate contents into the waste
container. The microtiter wells were rinsed and flicked five times with washing buffer
(1X). The wells were then struck sharply onto an absorbent paper to remove all residual
water droplets. Next, 100µl of TMB solution was dispensed into each well and gently
mixed for five seconds and then incubated in the dark at RT for 20 minutes. Adding
100µl of Stop Solution to each well, and gently mixing for thirty seconds stopped the
reaction. The results were read by optical density at 450nm with a microtiter well reader
(AccuDiag, Diagnostic Automation/Cortez Diagnostics Inc.).
Igf1 ELISA
One hundred microliters of standards, experimental samples (1:100 dilution with
Assay Diluent A), and controls were dispensed into the appropriate wells and covered
while gently shaking for two and a half hours. Next, the solution in each well was
decanted and washed with 300 microliters of 1xWash Buffer four times, decanting after
each successive wash. The wells were then struck sharply onto an absorbent paper to
remove all residual water droplets. Next, 100µl of the prepared biotin antibody (mouse
Igf1) was added to each well and incubated for one hour. The solution in each well was
decanted and washed with 300 microliters of 1xWash Buffer four times, decanting after
each successive wash. The wells were struck sharply onto an absorbent paper to remove
all residual water droplets. Next, 110 microliters of prepared Streptavidin solution was
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added to each well and allowed to incubate for 45 minutes. The solution in each well was
decanted and washed with 300 microliters of 1xWash Buffer four times, decanting after
each successive wash. The wells were struck sharply onto an absorbent paper to remove
all residual water droplets. Next, 100 microliters of 3,3’,5,5’-Tetramethylbenzidine
(TMB) One-Step Substrate Reagent was added to each well and allowed to incubate in
the dark for 30 minutes with gentle shaking. Adding 50µl of Stop Solution to each well
and gently mixing for thirty seconds stopped the reaction. The results were immediately
read by optical density at 450nm with a microtiter well reader (RayBio, Mouse IGF-1
ELISA kit).
ELISA Analysis
Total serum T4 or Igf1 levels were determined using the standard curve method.
Corresponding mean absorbance values from experimental samples were then
interpolated. The statistical significance of interpolated concentrations for P7-P21 was
analyzed using a two-way ANOVA to detect significant differences of treatment, time,
and an interaction between variables. A Bonferroni’s post-hoc t-test was then used to
identify significant differences between treatments. The interpolated concentrations for
P42 were analyzed by an unpaired t-test to determine significant differences between
treatments.
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Linear Regression Analysis
To determine whether a correlation between total serum T4 and total serum Igf1
existed on our experimental animals, serum from each individual animal was used to
investigate Igf1 and T4 levels. The matched serum values from animals at each age were
then plotted and analyzed by linear regression to determine significant correlation
between Igf1 and T4 serum levels.

Results
Pup Weights
Figure 3 summarizes mean pup body weights at time of sacrifice. No significant
effect of treatment was detected at P7 or P42. However, hypothyroid pup body weights
were significantly reduced compared to controls at P14 and P21.
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Figure 3. The effect of developmental hypothyroidism on pup body weights. Bars represent mean weight ±
standard error at indicated developmental age. (P) postnatal day. Two-way ANOVA indicated significant
effect of treatment (p<0.0001), time (p<0.0001), and an interaction between the variables (p<0.001).
Unpaired t-test indicated no significant effect of treatment at P42. Bonferroni’s post hoc, *p<0.01 between
control and hypothyroid animals, ****p<0.0001 between control and hypothyroid animals.

Serum T4
Figure 4 summarizes mean serum T4 at the time of sacrifice. Serum T4 was
significantly lower in hypothyroid animals at P14 and P21 when compared to their
respective control animals. No significant differences were observed between control and
treated animals at P7 or P42.
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Figure 4. The effect of developmental hypothyroidism on serum T4 concentrations as measured by ELISA.
Bars represent mean serum T4 ± standard error at indicated developmental ages. (P) postnatal day. Twoway ANOVA indicated significant effect of treatment (p<0.0001), time (p<0.01), and no interaction
between the variables. Unpaired t-test indicated no significant effect of treatment at P42. Bonferroni’s post
hoc, ***p<0.001 between control and hypothyroid animals, **p<0.01 between control and hypothyroid
animals.

Serum Igf1
Figure 5 summarizes mean serum Igf1 at the time of sacrifice. Serum Igf1 was
significantly lower in hypothyroid animals when compared to their respective controls at
P14 and P21. No significant differences were observed between control and treated
animals at P7 or P42.
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Figure 5. The effect of developmental hypothyroidism on serum Igf1 as measured by ELISA. Bars
represent mean serum Igf1 ± standard error at indicated developmental ages. (P) postnatal day. Two-way
ANOVA indicated significant effect of treatment (p<0.0001), time (p<0.05), and an interaction between the
variables (p<0.05). Unpaired t-test indicated no significant effect of treatment at P42. Bonferroni’s post
hoc, **p<0.01 between control and hypothyroid animals.

Correlation Between Serum T4 and Serum Igf1
Figure 6 demonstrates the relationship between matched serum T4 and serum Igf1
in animals at all ages tested (P7, P14, P21, and P42). A significant positive correlation
between total serum T4 and serum Igf1 was observed.
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Figure 6. The correlation between serum Igf1 and serum T4. Data compiled from animal matched serum
samples of control (blue) and hypothyroid (red) animals at P7 (circle), P14 (square), P21 (triangle), and P42
(diamond). Linear regression showed a significant deviation of the slope from zero (p<0.0001; R2=0.4951).

In Situ Hybridization
Figure 7 demonstrates Igf1-positive cell distribution observed in the three
identified regions of the brain analyzed at each developmental age.
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Figure 7. Distribution of Igf1 mRNA in the developing mouse (A) frontal motor cortex, (B) hippocampus,
and (C) cerebellum. (A) Positively stained Igf1 cells are apparent throughout the cortex, peaking around
P14 and declining thereafter, with control animals consistently showing higher levels of mRNA when
compared to hypothyroid animals at all ages. Solid black bar indicates midline (longitudinal fissure). (B)
Igf1-positively stained cells are most apparent in the strata oriens, radiatum, and lacunosum-molecular
regions, along with the dentate gyrus. Igf1 mRNA levels appear to peak around P7-P14 declining
thereafter, and show no visual differences in expression between treatments. (C) A strong Igf1 mRNA
signal is located within the purkinje cell layer (PCL), with expression appearing to peak around P7-P21,
declining thereafter. For all images, dashed black bar represents 250um.

Igf1-Postive Cell Numbers
Figure 8 summarizes the mean number of Igf1-positive cells in the cortex,
hippocampus, and cerebellum. Hypothyroid treated animals had significantly fewer Igf1positive cell numbers in the cortex at all developmental ages investigated compared to
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controls. No significant differences in the numbers of Igf-1 positive cells between control
and treated animals were detected in the hippocampus or cerebellum.
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Figure 8. The effect of developmental hypothyroidism on the mean number of Igf1-positive cells in the (A)
cortex, (B) hippocampus, and (C) cerebellum. Bars represent mean number of Igf1-positive cells ±
standard error at indicated developmental ages. (P) postnatal day. Red bars represent hypothyroid treatment
compared to percent of control. Dotted horizontal line represents control treatment as percent control value.
Two-way ANOVA indicated significant effect of treatment (p<0.0001) for the cortex (A) and no other
region. Unpaired t-test revealed no significant effect of treatment at P42. Bonferronis post hoc, *p<0.05
between control and hypothyroid animals, ***p<0.001 between control and hypothyroid animals,
****p<0.0001 between control and hypothyroid animals.

Integrated Density
Figure 9 summarizes relative cellular Igf1 mRNA levels determined by
quantifying the in situ hybridization signal as a gray scale and area of the signal
(integrated density). No significant differences between control and treated animals were
measured in the cortex, hippocampus, or cerebellum.
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Figure 9. The effect of developmental hypothyroidism on Igf1-positive cells integrated density measured
by gray scale values in the (A) cortex, (B) hippocampus, and (C) cerebellum. Bars represent mean
integrated density ± standard error at each indicated developmental age. (P) postnatal day. Two-way
ANOVA indicated no effect of treatment (p=0.0959), time (p=0.2287), or an interaction (p=0.2569).
Unpaired t-test revealed no significant effect of treatment at P42.

Discussion
In the mammalian brain, growth factors are the main components that control cell
proliferation, differentiation, and survival (Abe 2000). Out of the many growth factors
contributing to the development of the central nervous system, thyroid hormone is known
to interact with Igf1, a vital growth factor for the developing central nervous system
(Elder, Karayal et al. 2000). It is also known that TH is essential for proper Igf1 levels in
the serum and the brain
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(Elder, Karayal et al. 2000, Iglesias, Bayon et al. 2001, Poguet, Legrand et al. 2003).
However, the mechanistic relationship that TH and Igf1 share is poorly defined.
During the development of the central nervous system inadequate levels of TH or
Igf1 results in similar neuroanatomical defects. Considering this, we sought to test the
hypothesis that some of the developmental defects observed between low TH and Igf1
might be due to an altered temporal expression of Igf1 in the brain of hypothyroid
animals as compared to control animals. To test this, we rendered pregnant dams
hypothyroid through the administration of two well-known goitrogens - methimizole and
potassium perchlorate – and then quantified Igf1-positive cells and relative Igf1 mRNA
levels.

Effects of Treatment on Serum TH and Igf1 Levels
Induction of a hypothyroid state was confirmed by measuring serum T4
concentrations by ELISA (Figure 4). Furthermore, growth was severely retarded in
treated animals; an effect consistent with hypothyroidism and Igf1 deficiency
(MacGillivray, Aceto et al. 1968, Woods, Camacho-Hubner et al. 1996). However, once
goitrogen treatment was withdrawn, serum T4 levels normalized (Figure 4) and body
weight returned to normal (Figure 3), suggesting a return to euthyroidism.
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Hypothyroidism has been previously shown to cause a reduction in serum Igf1 (Holder
and Wallis 1977). Our results support this finding, such that hypothyroid treated
animals, when compared to controls, resulted in a significant reduction in serum Igf1 at
ages P14 and P21, when T4 was also significantly reduced (Figures 4 and 5). This
observation likely resulted from a disruption of the GH-axis induced by low TH. Thyroid
hormone directly regulates pituitary GH secretion, which in turn regulates Igf1
production in the liver (Nanto-Salonen, Glasscock et al. 1991). In addition, once serum
T4 recovered after the withdrawal of goitrogens, Igf1 levels in the serum also recovered
(Figures 4 and 5). Furthermore, our results indicate that there is a significant positive
correlation between circulating levels of T4 and Igf1. That is, as TH levels decrease in
the serum, Igf1 also decreases (Figure 6). This observation further supports that idea that
reductions in serum Igf1 described above are due to the indirect effect of TH on pituitary
GH secretion.
As stated previously, the regulation of serum Igf1 differs from local brain Igf1 in
that GH plays no regulatory role brain synthesis (Bondy and Cheng 2004, Aberg, Brywe
et al. 2006). Additionally, Igf1 does not easily cross the blood brain barrier; suggesting
that serum Igf1 is separate from locally brain derived Igf1 (Russo, Gluckman et al. 2005).
In the present study, we found that low TH was associated with a significant reduction in
Igf1-positive cells in the frontal motor neocortex at all developmental ages investigated,
but not in the hippocampus or cerebellum. Notably, a significant reduction was seen at
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P42, after goitrogen withdrawal, and TH levels were restored to normal; suggesting a
permanent loss in Igf1-positive cells (Figure 8). Considering that brain Igf1 levels appear
to not be regulated by GH, this observation suggests that the observed changes in Igf1positive cells is likely not due to altered GH signaling in TH deficient animals.
Interestingly, developmental and region specific reductions in brain Igf1 mRNA have
been previously recorded in hypothyroid rats (Elder, Karayal et al. 2000). However, it is
not clear from the previous study whether the observed decrease in Igf1 mRNA was due
to changes in the transcriptional levels of Igf1 or a loss of Igf1-positive cells.
The survival of neurons has previously been shown to depend on TH (Nunez
1984, Heisenberg, Thoenen et al. 1992). Additionally, neurons have also been identified
as the principle sites of Igf1 mRNA expression (Bartlett, Li et al. 1991). These reports
support the idea that TH has the potential to alter the total number of Igf1-positive cells in
the cortex, with hypothyroidism resulting in decreased Igf1-positive cells. Thyroid
hormone has also been shown to increase neuroblast proliferation and neuronal
proliferation (Montero-Pedrazuela, Venero et al. 2006). Furthermore, TH is responsible
for regulating the differentiation and maturation of astrocytes and stimulating growth
factor production, including Igf1 (Rodier 1980, Trentin 2006). Considering these reports
and the similarity in neuroanatomical defects between low TH or Igf1 in development, it
is reasonable to suggest that the negative effects hypothyroidism has on the developing
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nervous system are, in part, due to low TH preventing progenitor pool proliferation,
maturation, and/or survival of Igf1-positive cells. Loss of neuronal progenitors that
expand the Igf1-positive population would ultimately result in decreased levels of Igf1
mRNA in the brain.
Igf1 is reported to stimulate neural progenitor cell proliferation and differentiation
into oligodendrocytes (D'Ercole, Ye et al. 1996, Hsieh, Aimone et al. 2004). In Igf1
knockout mice, the percentage of OPCs and mature oligodendrocytes was reduced in all
regions of the brain (Ye, Li et al. 2002). Similarly, in mice lacking the Igf1r, a reduction
in neural/glial antigen 2 (NG2)-positive and allophycocyanin (CC1)-positive
oligodendrocytes was reported. This reduction was assumed to be a result from reduced
cell survival and growth, especially considering Igf1’s protective role against apoptosis
and its positive influence on proliferation, differentiation, and maturation of
oligodendrocytes and neurons (Chesik, De Keyser et al. 2008). Conversely, the addition
of exogenous Igf1 administration to rats resulted in an increase of progenitor cell
proliferation within the dentate gyrus (Dempsey, Sailor et al. 2003). Interestingly, similar
defects in myelination are reported in the hypothyroid brain (Baas, Bourbeau et al. 1997).
In cases of hypothyroidism, the total amount of myelination is decreased compared to
controls, most likely a result of delayed expression of MAG, a differentiated property of
oligodendrocytes (Gravel, Sasseville et al. 1990, Rodriguez-Pena, Ibarrola et al. 1993).
Thyroid hormone has been identified in controlling the accumulation of mature
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oligodendrocytes as well (Billon, Jolicoeur et al. 2002). These studies, along with the
present results, suggest that specific neuroanatomical defects observed between low TH
and low brain Igf1 may be due to a reduction in Igf1-positive cells, which could result in
an overall reduction in brain Igf1 mRNA levels.
In addition to the effects on oligodendrocytes, low TH or Igf1 in development are
known to reduce PCNs (Beck, Powell-Braxton et al. 1995, Gilbert, Sui et al. 2007).
Considering our observations, it would be interesting to investigate whether the PCNs
that are lost in the cortex and hippocampus are also responsible for synthesizing Igf1,
with their loss ultimately decreasing the amount of Igf1mRNA and parvalbumin in the
brain. This phenocopy between TH and local brain Igf1 on PV-IR could therefore be a
result from the TH-induced reduction of Igf1-positive cells in the brain.
To determine whether neuroanatomical defects associated with hypothyroidism
are due to a loss of Igf1 mRNA, Igf1 could be infused into the hypothyroid brain, or,
alternatively, a transgenic model could be used to exogenously drive Igf1 during
hypothyroidism.

Spatially Specific Effects of Low TH on Igf1-Positive Cells
Our results indicate the effect that hypothyroidism has on Igf1-positive cells
occurs in a region dependent matter, with no reductions of Igf1-positive cell numbers
found in the hippocampus or cerebellum, unlike the cortex (Figure 8). Differential
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sensitivity to TH has previously been found in RC3 (neurogranin), with no relation to
differential expression of TR isoforms. Hypothyroid rats had decreased expression of
RC3 in regions such as the dentate gyrus, but not the pyramidal layers of the
hippocampus. Decreased expression was also seen in layer six of the cerebral cortex,
unlike the upper layers of the cerebral cortex. In terms of the regulation of gene
expression, this leads us to believe that TR interacting factors, such as co-activators or
co-repressors, have input in determining whether a population of neurons will be
sensitive or not to TH (Guadano-Ferraz, Escamez et al. 1997).

Distribution of Igf1-Positive Cells in the Developing Brain
Cells positive for Igf1 mRNA in the neocortex appeared scattered with no
discernible layer enrichment. Qualitatively, Igf1 mRNA peaked between P7-P14, with
Igf1 mRNA declining thereafter (Figure 7). Although the present study is unable to
define which cell type is positive for Igf1, reports from others has suggested that Igf1postive cells in the cortex are neuronal in nature (Bartlett, Li et al. 1991). In the
hippocampus, Igf1-positive cells were identified in the strata oriens, radiatum and
lacunosum-molecular regions with peak expression occurring at approximately P7
(Figure 7). These hippocampal Igf1-positive cells have been previously described as
being large polymorphic neurons (Bartlett, Li et al. 1991). In the cerebellum, Igf1positive cells were restricted to the Purkinje cell layer (PCL) with peak expression of Igf1
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mRNA occurring from P7-P21 (Figure 7). Within the cerebellum, the majority of
proliferation and differentiation of migrating granule cells occurs after birth. Considering
this, sustained postnatal Igf1 may play a role in this process, as proposed by Bartlett and
Li (Bartlett, Li et al. 1991). This may explain why expression does not as rapidly decline
after P14, like in other regions discussed. These observed patterns of Igf1 mRNA are
consistent with those previously reported in the hippocampus and cerebellum (Bartlett, Li
et al. 1991).
Due to the variability within the ISH (in situ hybridization) assay and the need to
normalize to percent of control, it was impossible to detect temporal changes. However,
previous findings have found that local brain Igf1 expression occurs in a time dependent
matter, with its peak expression occurring in early postnatal life, declining thereafter
(Bondy 1991, D'Ercole, Ye et al. 1996). In the rat brain, peak Igf1 expression occurs in
late gestation through weaning, matching the time in which TH is essential for normal
brain development (Bach, Shen-Orr et al. 1991, Porterfield 1994). This can also be seen
in serum Igf1, with peak serum T4 correlating to peak Igf1 in the serum (Figures 4 and
5). When hypothyroidism is induced in adult mice, Igf1mRNA does not differ between
control and hypothyroid animals, indicating that during development is when it is most
critical for the nervous system (Elder, Karayal et al. 2000).
Neurons have previously been implicated as being the principle sites of
Igf1mRNA expression, with some evidence also suggesting that neuroglia in some brain
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regions may also express Igf1, like that of astrocytes found in forebrain fiber tracts
(Bartlett, Li et al. 1991). However, further investigation through dual labeled
immunohistochemistry is needed in identifying the precise cells that synthesize Igf1 in
the brain.

Treatment Effects on Cellular Igf1 mRNA Levels
Our results indicated no effect of treatment on relative Igf1 mRNA per Igf1positive cell in any of the investigated brain regions (Figure 9). This observation suggests
that the decrease seen in Igf1 mRNA in the brain measured by others (Elder, Karayal et
al. 2000) is not from a reduction in TH-mediated regulation of Igf1 mRNA synthesis
through its receptors. This further suggests that hypothyroidism does not inhibit brain
cells capacity to synthesize Igf1, but rather there is a loss of Igf1 secreting cells, which
would result in a decrease in total brain Igf1 mRNA. However, in the current study, we
cannot exclude the possibility that Igf1-positive cells are present in the cortex, but Igf1
mRNA levels were below the detection of the assay, rather than completely absent.
Furthermore, the levels of expression of local brain Igf1 mRNA in the current study did
not significantly differ from when treatment was being administered, to when it was
halted, further concluding that TH does not inhibit the synthesis of Igf1, but rather the
accumulation of Igf1-positive cells (Figure 9). However, the possibility exists that the
Igf1-positively stained cells had reached saturation in the enzymatic reaction of the ISH
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assay, which would have made detection of small changes in Igf1 mRNA synthesis
impossible to observe, and potentially could have masked differences of Igf1 mRNA
between treatments. Qualitative-PCR could be used in future investigation to examine the
possibility of small changes and differences in Igf1 mRNA over time and between
treatments, which may not have been detectable by the current studies utilized assay.
Thyroid hormone acts on its associated nuclear receptors to effect gene
transcription (Bernal 2002, Bernal 2007). Although many of TH affects are indirect, a
TRE in intron 1 of the Igf1 gene has been identified and reported to directly regulate Igf1
gene transcription in bone (Xing, Govoni et al. 2012). In the present study, we observed a
significant permanent loss in Igf1-postive cells following developmental hypothyroidism
(Figure 8). However, Igf1-positive cells that remained appeared to have normal levels of
Igf1 mRNA (Figure 9). One possible explanation for this finding is that in the
developing brain, TH and its receptors do not control the rate of Igf1 transcription. This
conclusion would imply that another, unidentified mechanism controls Igf1 transcription.
Consistent with this idea, in the other regions analyzed, neither the numbers of Igf1positive cells or relative amounts of Igf1 mRNA we reduced (Figures 8 and 9);
suggesting TH-independent regulation in the cerebellum and hippocampus.
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Concluding Remarks and Future Studies
Thyroid hormone negatively alters the amount of Igf1-positive cells within
specific regions of the developing brain (Figure 8). Additionally, we show that the
synthesis of Igf1 mRNA from brain cells is most likely not directly dependent on TH
(Figure 9). Furthermore, a region specific expression of Igf1-positive cells is shown
(Figure 8), demonstrating that Igf1-positive cells in the cortex may be directly regulated
by TH, whereas in regions such as the hippocampus and cerebellum, there is the potential
for additional regulatory TR interacting factors controlling Igf1 mRNA synthesis. The
evidence presented previously, along with these findings, make it tempting to suggest that
the loss of TH causes a reduction of local brain Igf1 by decreasing the amount of Igf1
synthesizing cells, resulting in hypothyroid associated neuroanatomical defects. Based on
preliminary data, a rescue group, consisting of the hypothyroid treatment with the
addition of exogenous T4 resulted in control-like levels of serum T4, indicating that the
reductions in serum TH, serum Igf1, and Igf1-positive cells in the frontal motor cortex
are a result of the induced hypothyroidism, not the drug. However, more investigation is
needed to further solidify this evidence.
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